Skip to content

Telix Pharmaceuticals Ltd Price, Chart & Factor Exposure

Free Data & Analytics Access
Telix Pharmaceuticals Ltd · E.TLX.AU · Australia
Use symbol E.TLX.AU in our API & Excel add-in to retrieve this data ↓
12.92
(-0.02%)
? Live Prices updated every 5-seconds. Momentum Factor ranges from -100 to +100 and is the mean of four timeframe signals (1 Day, 1 Week, 1 Month, 3 Months), where each timeframe is +1 if return is above 0 and -1 otherwise. Trend Factor ranges from -100 to +100 and is the mean of eight signals across 1-month, 3-months, 6-months, and 1-year, using price vs moving average and moving average slope (+1 or -1). A rollover occurs when trend flips sign. Bubble Risk is the z-score of current price vs 1-year price: (Current Price - 250 trading days SMA) / (250 days price standard deviation). Values above +2.5 indicate overbought; below -2.5 oversold. Realized Volatility (20-days) is the standard deviation of daily returns over the past 20 trading days multiplied by sqrt(252).
Momentum -100%
Trend -100%
Bubble Risk LOW
Realised Volatility (20D) 35.87%

Telix Pharmaceuticals Ltd Forecast

Telix Pharmaceuticals Ltd short-term momentum is strongly negative (up over 0 of 4 look-backs: 5, 10, 20 and 30 trading days), a short-term SELL signal. The long-term trend is strongly negative (0 of 8 checks up: price above, and slope of, its 50-, 100-, 150- and 200-day averages), a long-term SELL signal. Based on 20-day realised volatility of 35.9% a year, a typical one-standard-deviation range is 12.27–13.57 over a week, 11.58–14.26 over a month and 8.2854–17.55 over a year. (Signals as of 21 Nov 2026.)

Telix Pharmaceuticals Ltd Price Chart

MacroFinance.ai

Telix Pharmaceuticals Ltd Factors

Test factors in Return analysis →
Market/MacroIndicatorNowChangeRange
Quantitative
Telix Pharmaceuticals Ltd
Momentum (composite)
—
ⓘLatest reading of Momentum (composite).
Telix Pharmaceuticals Ltd
Relative Volume (21d)
—
ⓘLatest reading of Relative Volume (21d).
Telix Pharmaceuticals Ltd
Signal
0
ⓘLatest reading of Signal.
Fundamental
Valuation
Telix Pharmaceuticals Ltd
P/E
66.98x
Cheap vs own history
QoQ −17.3%
YoY −2.9%
now 66.975659.22 low122.79 high
ⓘP/E As of 22 Nov 2026.See Telix Pharmaceuticals Ltd returns when P/E looked like now →Opens Return analysis with the filter P/E within ±5% of today
Telix Pharmaceuticals Ltd
P/S
2.51x
Cheap vs own history
QoQ −17.3%
YoY −23.2%
now 2.51391.91 low3.61 high
ⓘP/S As of 22 Nov 2026.See Telix Pharmaceuticals Ltd returns when P/S looked like now →Opens Return analysis with the filter P/S within ±5% of today
Telix Pharmaceuticals Ltd
P/B
9.46x
Cheap vs own history
QoQ −17.3%
YoY −14.5%
now 9.45927.14 low13.07 high
ⓘP/B As of 22 Nov 2026.See Telix Pharmaceuticals Ltd returns when P/B looked like now →Opens Return analysis with the filter P/B within ±5% of today
Telix Pharmaceuticals Ltd
EV/EBITDA
42.90x
Mid-range vs own history
QoQ −16.3%
YoY +27.8%
now 42.901122.9 low58.18 high
ⓘEV/EBITDA As of 22 Nov 2026.See Telix Pharmaceuticals Ltd returns when EV/EBITDA looked like now →Opens Return analysis with the filter EV/EBITDA within ±5% of today
Telix Pharmaceuticals Ltd
EV/Sales
2.69x
Cheap vs own history
QoQ −16.3%
YoY −21.3%
now 2.69262.12 low3.76 high
ⓘEV/Sales As of 22 Nov 2026.See Telix Pharmaceuticals Ltd returns when EV/Sales looked like now →Opens Return analysis with the filter EV/Sales within ±5% of today
Telix Pharmaceuticals Ltd
FCF Yield
-1.4%
Mid-range vs own history
QoQ +20.9%
YoY +502.4%
now -1.3825-2.56 low-0.21 high
ⓘFCF Yield As of 22 Nov 2026.See Telix Pharmaceuticals Ltd returns when FCF Yield looked like now →Opens Return analysis with the filter FCF Yield within ±5% of today
Telix Pharmaceuticals Ltd
Earnings Yield
1.5%
Strong vs own history
QoQ +20.9%
YoY +3.0%
now 1.49310.81 low1.69 high
ⓘEarnings Yield As of 22 Nov 2026.See Telix Pharmaceuticals Ltd returns when Earnings Yield looked like now →Opens Return analysis with the filter Earnings Yield within ±5% of today
Telix Pharmaceuticals Ltd
Market Cap
$4.6B
Mid-range vs own history
QoQ −17.3%
YoY −0.8%
now 4611.02012,968 low6,370 high
ⓘMarket Cap As of 22 Nov 2026.See Telix Pharmaceuticals Ltd returns when Market Cap looked like now →Opens Return analysis with the filter Market Cap within ±5% of today
Balance-Sheet Health
Telix Pharmaceuticals Ltd
Net Debt
$328M
High vs own history
QoQ 0.0%
YoY +54.5%
now 327.809212.2 low327.81 high
ⓘNet Debt As of 22 Nov 2026.See Telix Pharmaceuticals Ltd returns when Net Debt looked like now →Opens Return analysis with the filter Net Debt within ±5% of today
Telix Pharmaceuticals Ltd
Net Debt / EBITDA
2.85x
2.85x
QoQ 0.0%
YoY +94.2%
now 2.84751.47 low2.85 high
ⓘNet Debt / EBITDA As of 22 Nov 2026.See Telix Pharmaceuticals Ltd returns when Net Debt / EBITDA looked like now →Opens Return analysis with the filter Net Debt / EBITDA within ±5% of today
Telix Pharmaceuticals Ltd
Current Ratio
2.01x
Mid-range vs own history
QoQ 0.0%
YoY +51.1%
now 2.01381.33 low2.01 high
ⓘCurrent Ratio As of 22 Nov 2026.See Telix Pharmaceuticals Ltd returns when Current Ratio looked like now →Opens Return analysis with the filter Current Ratio within ±5% of today
Telix Pharmaceuticals Ltd
Quick Ratio
1.85x
Mid-range vs own history
QoQ 0.0%
YoY +52.5%
now 1.85271.22 low1.85 high
ⓘQuick Ratio As of 22 Nov 2026.See Telix Pharmaceuticals Ltd returns when Quick Ratio looked like now →Opens Return analysis with the filter Quick Ratio within ±5% of today
Telix Pharmaceuticals Ltd
Interest Coverage
1.26x
1.26x
QoQ 0.0%
YoY −52.5%
now 1.2631.26 low2.66 high
ⓘInterest Coverage As of 22 Nov 2026.See Telix Pharmaceuticals Ltd returns when Interest Coverage looked like now →Opens Return analysis with the filter Interest Coverage within ±5% of today
Telix Pharmaceuticals Ltd
Debt / Equity
1.19x
High vs own history
QoQ 0.0%
YoY +18.8%
now 1.1891 low1.19 high
ⓘDebt / Equity As of 22 Nov 2026.See Telix Pharmaceuticals Ltd returns when Debt / Equity looked like now →Opens Return analysis with the filter Debt / Equity within ±5% of today
Telix Pharmaceuticals Ltd
Piotroski F-Score
3
3
QoQ 0.0%
YoY +50.0%
now 31 low3 high
ⓘPiotroski F-Score As of 22 Nov 2026.See Telix Pharmaceuticals Ltd returns when Piotroski F-Score looked like now →Opens Return analysis with the filter Piotroski F-Score within ±5% of today
Telix Pharmaceuticals Ltd
Altman Z-Score
4.79
Weak vs own history
QoQ −12.1%
YoY −5.8%
now 4.78793.89 low6 high
ⓘAltman Z-Score As of 22 Nov 2026.See Telix Pharmaceuticals Ltd returns when Altman Z-Score looked like now →Opens Return analysis with the filter Altman Z-Score within ±5% of today
  14 members-only factors: FCF Growth, Earnings Surprise, Estimate Revision 30D, Forward P/E and moreSign up
Accounting Red Flags
  17 members-only factors: Sloan Accruals, Cash-Earnings Gap, Beneish M-Score, Days Sales in Receivables Index and moreSign up
Global Risk
  22 members-only factors: MacroFinance Risk Index, VIX, VSTOXX, VIX Term Structure and moreSign up
Teal = supportive for Telix Pharmaceuticals Ltd, red = a headwind, grey = neutral. Hover or tap ⓘ for how each factor works and to see returns in similar conditions.

Telix Pharmaceuticals Ltd fundamentals: income statement, balance sheet & cash flow

Telix Pharmaceuticals Ltd reported revenue of 816.7m AUD and net income of -7.2m AUD in FY2025, the year ended 31 December 2025 — revenue up 4.3% and net income down 114.5% on the prior year. Free cash flow was -56.1m AUD. These figures are as reported in the filings, not restated: 13 fiscal years and 44 quarters of history, back to December 1999.

Revenue (FY2025)
816.7m AUD
+4.3%
Net income
-7.2m AUD
-114.5%
Gross margin
53.11%
Free cash flow
-56.1m AUD
-723.5%
Net debt
325.0m AUD
Telix Pharmaceuticals Ltd income statement, annual, as reported · AUD millions unless stated
AUD millionsFY2025FY2024FY2023FY2022FY2021
Period end31 Dec 202531 Dec 202431 Dec 202331 Dec 202231 Dec 2021
Revenue816.7783.2502.5160.17.6
Cost of revenue382.9273.5188.2130.837.4
Gross profit433.8509.7314.429.3-29.8
Research & development174.0194.6128.857.934.1
Selling, general & admin.241.7———17.3
Operating income18.182.152.6-73.2-81.2
EBITDA40.290.123.1-92.8-70.1
Interest expense37.321.51.00.40.2
Pre-tax income-5.456.13.1-98.6-99.0
Income tax1.96.1-2.15.5-18.5
Net income-7.249.95.2-104.1-80.5

Download Telix Pharmaceuticals Ltd fundamentals

Get the fundamentals as
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_fundamentals&symbol=E.TLX.AU&statement=all&freq=a&format=csv&years=10
DownloadLast 10 fiscal years, no login.
The free download stops at 10 fiscal years. A free account unlocks all 13 fiscal years and 44 quarters, the filing vintages behind each number and API access.
Create free account

Figures in AUD, statements as filed. A cell is left blank where the filing does not report it or where the reported figure fails the statement’s own arithmetic.

Research on Telix Pharmaceuticals Ltd

Explore MacroFinance macro & markets research and analysis.

Browse all financial research →

Telix Pharmaceuticals Ltd Trading Strategies

31 backtested tactical asset allocation strategies hold EFA (developed markets outside the US), the closest tradable exposure to Telix Pharmaceuticals Ltd; 22 of them are invested now. Strategies currently invested are listed first.

Hypothetical backtests over each ETF's own history; past performance does not guarantee future results. Upgrade to see every strategy's allocation and performance.

See all 31 strategies holding EFA →

Statistical Distribution of Returns

Plus

How Telix Pharmaceuticals Ltd’s returns are distributed — and how they change in a given market regime.

Regime filters

Market/Macro Indicator Criteria Value And (for Between) Action

No regime filter yet — the chart below shows every period. Add a factor condition, or pick a popular regime.

MacroFinance.ai
Full return statistics
Statistic All periods Matching
  Sharpe, maximum drawdown and the full percentile table are part of Plus. Unlock with Plus
Know how Telix Pharmaceuticals Ltd behaves before the regime turns Plus unlocks the full return history, unlimited factor conditions, regime-versus-baseline statistics and export — on every market, stock, ETF and index.

About Telix Pharmaceuticals Ltd (Australia)

Telix Pharmaceuticals Ltd is a listed security in Australia. This page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data (the last 10 years as CSV or JSON, no login).

Last updated: November 22, 2026

More on Talanx AG

Frequently asked questions

What is Telix Pharmaceuticals Ltd?
Telix Pharmaceuticals Ltd is a listed security in Australia. On MacroFinance its page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data.
What is the latest Telix Pharmaceuticals Ltd price?
The latest close is 12.92 (21 Nov 2026), -0.02% on the day. The price at the top of the page refreshes during the trading day.
Is Telix Pharmaceuticals Ltd in an uptrend?
As of 21 Nov 2026, short-term momentum is strongly negative (0 of 4 look-backs up: 5, 10, 20 and 30 trading days) and the long-term trend is strongly negative (0 of 8 checks up on its 50- to 200-day moving averages). Bullish when both are positive, bearish when both are negative.
How volatile is Telix Pharmaceuticals Ltd?
20-day realised volatility is 35.9% a year (21 Nov 2026), which implies a typical one-standard-deviation move of about 10.4% over a month and 5.1% over a week.
What factors affect Telix Pharmaceuticals Ltd?
The Factors section lists the signals, relative-value, risk-model and macro factors linked to Telix Pharmaceuticals Ltd, grouped as Quantitative Factors, Fundamental Factors, Accounting Red Flags, Global Risk Factors, each with its latest reading. Some factors are open to everyone; the rest need a MacroFinance plan.
Which trading strategies trade Telix Pharmaceuticals Ltd?
31 backtested tactical asset allocation strategies trade Telix Pharmaceuticals Ltd through EFA; 22 of them hold it now. The Trading Strategies section lists them with their current weight, CAGR, Sharpe ratio and maximum drawdown.
How are Telix Pharmaceuticals Ltd returns analysed?
The Statistical Distribution of Returns section shows the distribution of Telix Pharmaceuticals Ltd daily, weekly, monthly, 2-month and 3-month returns with count, annualised average return, volatility, Sharpe ratio and maximum drawdown, and lets you filter the history by factor conditions, e.g. only periods when momentum was positive. A free account tests up to 2 factor conditions over the last 1 year of history; a Plus plan unlocks the full history, unlimited conditions, the regime statistics and the export.
Where can I download free Telix Pharmaceuticals Ltd historical data?
In the Free historical data section of this page: the last 10 years of Telix Pharmaceuticals Ltd daily closes as CSV or JSON, no login needed. A free account unlocks the full history, Excel and API access.

Free Telix Pharmaceuticals Ltd historical data (last 10 years)

Browse or instantly download the last 10 years of Telix Pharmaceuticals Ltd daily price history. A free account unlocks the full history, an Excel export with factors, and API access.

Get the data as
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_history&symbol=E.TLX.AU&format=csv&years=10
DownloadLast 10 years, no login.
DateClose
2026-11-2012.92
2026-11-1913.22
2026-11-1813.21
2026-11-1713.33
2026-11-1613.39
2026-11-1313.58
2026-11-1213.7
2026-11-1114.02
2026-11-1013.8
2026-11-0913.93
Loading last 10 years…
The table and downloads stop at 10 years. A free account unlocks the full history, the Excel add-in and API access.
Create free account

About this stock

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney cancer; TLX101, a systemic therapy for the treatment of glioblastoma; TLX66, a product candidate for bone marrow conditioning for hematopoietic stem cell transplant conditioning; and Illuccix and Gozellix for the treatment of prostate cancer. The company is also developing TLX592, a prostate cancer therapy candidate for targeted alpha therapy based on its proprietary RADmAb-engineered antibody technology; TLX252 for the treatment of patients with advanced metastatic kidney cancer; TLX400, a bladder fibroblast activation protein for treating various tumors; TLX102, a large amino acid transporter-targeting small molecule-based alpha therapy candidate for the treatment of glioblastoma and multiple myeloma; TLX300 for treating soft tissue sarcoma; and TLX090, a bone-seeking agent for bone metastases and pain palliation. In addition, it is developing BiPASS, which is in Phase 3 clinical trial for prostate cancer diagnosis; AlFluor, a novel PET radiochemistry solution; TLX250-Px, a PET diagnostic imaging agent; and TLX101-Px, a radiolabeled amino acid PET agent. It operates in Australia, Belgium, Canada, the United Kingdom, the United States, and internationally. The company has strategic collaboration with University Hospital Essen. The company was founded in 2015 and is headquartered in North Melbourne, Australia.